CD markers

BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection.

PSB-12379 is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).

YYA-021 is a CD4-mimic HIV entry inhibitor.

AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). Inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases.

AX-024 is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.

MethADP is a specific CD73 inhibitor.

AB-680 is highly potent, reversible and selective small molecule inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity.

CD38 inhibitor 1 (compound 78c) is a potent CD38 inhibitor with IC50s of 7.3 nM and 1.9 nM for hCD38 and mouse CD38.

Sodium metatungstate (POM-1) is a potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor, with Ki values of 2.58 μM, 3.26 μM, and 28.8 μM for NTPDase 1, NTPDase 3 and NTPDase 2 respectively.

MethADP (sodium salt) is a specific CD73 inhibitor.

RWJ-60475 is a selective inhibitor of CD45 and CD148 tyrosine phosphatases, exhibiting an IC50 of 3.3 μM. By inhibiting these phosphatases, RWJ-60475 disrupts the phagocytic activity of macrophages, effectively blocking the invasion of Legionella pneumophila and the subsequent transport of effector proteins. This compound is valuable for research applications focused on anti-infection strategies that target host cellular factors.

RS17 is a CD47-SIRPα signaling inhibitor that disrupts the interaction between CD47 and its ligand, SIRPα, on macrophage surfaces. By binding to CD47, RS17 prevents the transmission of signals that enable selective phagocytosis, thereby promoting the recognition and clearance of tumor cells by macrophages. This peptide is valuable for researching anti-tumor responses and mechanisms of immune evasion in cancer.

IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration.

Sulfo-ara-F-NMN is a selective SARM1 activator and CD38 inhibitor, functioning as a mimetic of nicotinamide mononucleotide (NMN). It effectively activates SARM1 while inhibiting CD38, with an IC50 of approximately 10 μM. This compound is valuable for research applications focused on the modulation of intracellular cyclic ADP-ribose (cADPR) production and the exploration of pathways involving SARM1 and CD38 in cellular signaling.

LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM.

MK-0159 is an orally active, potent, and selective inhibitor of CD38, with IC₅₀ values of 22 nM for human, 3 nM for mouse, and 70 nM for rat CD38. It exhibits good microsomal stability in both human and rodent liver microsomes. MK-0159 effectively increases NAD⁺ (nicotinamide adenine dinucleotide) levels and decreases ADPR (adenosine diphosphate ribose) concentrations in whole blood and heart tissue, making it a promising compound for research in metabolic, cardiovascular, and age-related diseases.

RBN013209 is an orally active, small molecule inhibitor of CD38, exhibiting potent inhibitory activity with an IC₅₀ ranging from 0.01 to 0.1 μM against human CD38. It effectively blocks the enzymatic conversion of extracellular NAD⁺ to ADPR and cADPR in both tumor cells and peripheral blood mononuclear cells (PBMCs), thereby modulating the tumor microenvironment. Beyond its direct antitumor potential, RBN013209 also enhances the efficacy of immunotherapies. It preserves the naïve and central memory phenotypes of CAR-T cells, while reducing the expression of activation markers and exhaustion-associated inhibitory receptors. These properties position RBN013209 as a promising agent for both tumor research and the development of combination strategies to improve CAR-T cell persistence and function.

CD28-IN-3 is a selective CD28 inhibitor that effectively interrupts the CD28-B7 interaction, with an IC50 of 7.80 μM and a Kd of 52.45 μM. This compound significantly suppresses the production of key proinflammatory cytokines, including IFN-γ, IL-2, and TNF-α. CD28-IN-3 is valuable for research focused on checkpoint-resistant cancers, providing insights into immune modulation and potential therapeutic strategies.

CD28-IN-1 is a selective inhibitor of CD28 with a dissociation constant (KD) of 12.48 μM. It effectively disrupts the CD28-B7 interactions, leading to a significant reduction in CD28-mediated immune activation. This compound has been shown to suppress cytokine production, including IFN-γ, IL-2, and TNF-α, in primary human T cells when co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 is suitable for research focused on tumor immunity and T cell modulation.

DMUP is a potent inhibitor of the CD47-SIRPα axis. This compound promotes apoptosis and enhances macrophage phagocytosis in A549 lung cancer cells, while also reducing the expression of CD47 and SIRPα proteins. DMUP demonstrates significant antitumor activity, making it a valuable tool for research in cancer immunotherapy and macrophage biology.

Aritinercept is a recombinant fusion protein that functions as an inhibitor of TNFSF13B (BAFF/CD257). This compound effectively neutralizes BAFF and APRIL, leading to reduced B cell proliferation and suppression of peripheral B cells, along with a decrease in serum immunoglobulins. Aritinercept has demonstrated beneficial effects in a mouse model of systemic lupus erythematosus (SLE) by lowering markers of renal damage, as well as reducing levels of IFNγ, IL-17A, and anti-dsDNA autoantibodies. This reagent is suitable for research focused on systemic lupus erythematosus and related autoimmune disorders.

1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC is a unique oxidized phospholipid that functions as a potent CD36 inhibitor. It features palmitic acid at the sn-1 position and 13(S)-HODE at the sn-2 position, allowing it to interfere with the binding of 125I-NO2-LDL to CD36-transfected 293 cells, exhibiting an IC50 value greater than 200 μM. This compound is useful for research applications exploring lipid interactions and receptor signaling pathways associated with CD36.

GSC-718 is a synthetic sialoside and a potent inhibitor of CD22, exhibiting an IC50 value of 0.161 μM for mouse CD22. This compound is known to promote the proliferation of B cells and enhance antibody production. GSC-718 is particularly relevant for research applications involving B-cell lymphoma and autoimmune conditions such as rheumatoid arthritis.

CD28-IN-2 is a selective inhibitor of the CD28-B7 interaction, demonstrating an IC50 of 22.4 μM and a Kd value of 24.1 μM. This compound effectively inhibits CD28-mediated immune activation and prevents T cell costimulation. CD28-IN-2 serves as a valuable tool in research investigating antitumor immunity and various immune-related disorders.

Radanstobart is a humanized monoclonal antibody that selectively inhibits CD272, a checkpoint protein involved in immune regulation. This antibody exhibits significant antitumor activity, making it valuable for cancer research and immunotherapy studies. It is classified as a human IgG4κ isotype, providing a robust platform for investigating immune responses and potential therapeutic approaches targeting the tumor microenvironment.

B7/CD28 Interaction Inhibitor 1 is a selective inhibitor of the B7.1-CD28 interaction, exhibiting an IC50 of 50 nM. This compound disrupts T-cell costimulation, making it a valuable tool for research in immunology and cancer therapy. Its ability to modulate T-cell responses highlights its potential applications in studying immune regulation and developing immunotherapeutic strategies.

DDS5 is a selective CD28 inhibitor with an affinity (kd) of 175.57 µM, effectively disrupting the CD28-CD80 interaction with an IC50 value of 332 µM. This compound is instrumental in researching immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis, enabling investigations into immune response modulation and therapeutic strategies.

CVN14 is a selective and potent inhibitor of CD38, exhibiting inhibitory activity with human and mouse IC50 values of 19 nM and 2.4 nM, respectively. This compound binds uncompetitively to CD38, forming a complex with ADPR and subsequently inhibiting its enzymatic activity. CVN14 is suitable for research applications focused on neurodegenerative diseases, providing insights into the role of CD38 in these conditions.

Luteolinidin chloride is a potent inhibitor of CD38, with a Ki value of 11.4 μM, and demonstrates significant antioxidant activity. This compound has shown to protect cardiac tissue from ischemia/reperfusion injury by preserving the functionality of endothelial nitric oxide synthase (eNOS) and preventing endothelial dysfunction. Additionally, Luteolinidin chloride acts as a competitive inhibitor of tyrosinase, with an IC50 of 3.7 μM, effectively blocking melanin production. This makes it a valuable reagent for research in cardiovascular protection and skin pigmentation studies.

CD38 Inhibitor 2 is a selective inhibitor of CD38 with an IC50 range of 0.01 to 0.1 μM. This compound demonstrates potent inhibition of CD38 enzymatic activity, making it a valuable tool for studies focused on NAD+ metabolism and immune regulation. Its applications extend to cancer research, immunology, and age-related studies, contributing to a better understanding of the role of CD38 in various biological processes.

Ara-F-NAD+ is an arabino analogue of NAD+ and functions as a potent, reversible, and slow-binding inhibitor of CD38 NADase. This compound effectively modulates NAD+ metabolism, making it a valuable tool for studying the role of CD38 in various biological processes. Ara-F-NAD+ has potential applications in research focused on immune regulation, cellular signaling, and metabolic disorders related to NAD+ homeostasis.

6-Alkyne-F-araNAD is an irreversible inhibitor of CD38, a critical enzyme involved in the regulation of cyclic ADP-ribose and NAD metabolism. This compound enhances the efficacy of fluorescent probes, such as SR101-F-araNMN, allowing for improved visualization of intracellular CD38 localization. It serves as a valuable tool in studies related to immune signaling and cellular response mechanisms.

CD38-IN-5 is a selective inhibitor of CD38 hydrolase, exhibiting an IC50 of 4.0 μM, while sparing CD38 cyclase activity. This compound is particularly effective in enhancing natural killer (NK) cell-mediated tumor cytotoxicity and promotes increased levels of NADH+ and IFNγ in activated peripheral blood mononuclear cells (PBMCs). CD38-IN-5 serves as a valuable tool for cancer research, facilitating the investigation of immune modulation and tumor interactions.

(E/Z)-CCR-11 is a selective inhibitor of CD38, exhibiting an IC50 value of 20.8 μM against CD38 cyclase. This compound effectively enhances cellular NAD+ levels and promotes the production of interferon γ. It is valuable for research applications focused on cellular metabolism and immune response modulation.

HA-CD44 Interaction Inhibitor 2 is an inhibitor that targets the interaction between Hyaluronic acid (HA) and CD44. It exhibits antiproliferative effects on CD44-positive cancer cells, effectively disrupting cancer sphere integrity and decreasing cell viability in a dose-dependent manner. This compound is suitable for applications in tumor research aimed at understanding the role of CD44 in cancer progression.

HA-CD44 Interaction Inhibitor 1 is a specific inhibitor of the interaction between hyaluronic acid (HA) and CD44. By disrupting this interaction, it demonstrates significant antiproliferative effects on CD44+ cancer cell lines. This compound is valuable for research aimed at understanding cancer progression and potential therapeutic strategies targeting CD44-mediated cellular processes.

Evorpacept is a high-affinity CD47 inhibitor designed to block the CD47-SIRPα immune checkpoint interaction. By binding to CD47, Evorpacept facilitates the inhibition of wild-type SIRPα binding, enhancing immune response against tumors. This reagent is particularly relevant for research applications focused on acute myeloid leukemia and other malignancies where CD47 plays a pivotal role in immune evasion.